Mr. Wickholm has extensive senior management and leadership experience from AstraZeneca. He has a strong track record from general management and commercial roles covering various therapeutic areas. Mr Wickholm has also had international assignments and his last position in AstraZeneca was Regional Business Development CEEMEA, (Central-, Eastern- Europe, Middle East, Africa). In business development he has experience from both sell- and buy-side, from search, through assessments, evaluations, due diligence and negotiations to closure of deals.
Mr Wickholm has a BSc in Business Administration and Economics – International Business from Uppsala University and a Postgraduate diploma in Business Management and Finance from Warwick Business School, UK.
Andrew Saunders, M.D., FFPM, CMO (Chief Medical Officer)
Dr. Saunders is trained as a haematologist and has since 1992 worked with haemato-oncology drug development in both clinical practice and the pharmaceutical and biotech industry. He has extensive industry experience including large pharma (Roche, Eli-Lilly), Biotech (Biovision) and as founder and managing director of Linden Oncology Ltd, a specialist oncology consultancy.
Dr. Saunders obtained his medical degree from Trinity College Dublin, Rep. of Ireland in 1989 and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, London, U.K.
Wenche Marie Olsen, PhD, COO (Chief Operating Officer)
Dr. Olsen has extensive senior leadership experience within research, development and management of new drug products in pharmaceutical and biotech industry. Dr. Olsen was the CEO of Lauras, a Norwegian HIV biotech company, since start-up and has held various positions in Nycomed/GE Healthcare. Dr. Olsen has also broad experience from commercialization and business development from the Life Science sector (Oslo Research Park, 4BIO). In addition, she has held public board positions (the Norwegian Research Council, the Norwegian Bioindustry Association) and serves now as a board member in Medinnova.
Dr. Olsen received her PhD in medical biochemistry from the National Hospital, University of Oslo.
Øystein Rekdal, PhD, Co-founder and CSO (Chief Scientific Officer)
Dr. Rekdal has extensive research background within tumor immunology, oncolytic peptides and their abilities to induce potent tumor specific immune responses. Dr. Rekdal commenced his PhD on cytokines and tumor immunology in 1996. His postdoctoral work was focusing on oncolytic peptides and their abilities to induce potent tumor specific immune responses. This research forms the basis of Lytix Biopharma’s oncolytic peptide platform. Dr. Rekdal is leading the collaboration with several distinguished researchers and institutions to further explore the unique ability of oncolytic peptides to generate an immunogenic tumor microenvironment. He also serves as a professor at the University of Tromsø in Norway.
Dr. Furuseth has broad experience from most aspects within life sciences sector. Before joining Lytix Biopharma he was in the executive management team at Aker BioMarine responsible for Innovation, including science documentation, product development patent prosecution and litigation. He also has experience from sales processes, due diligence, negotiations and transactions in life sciences. Dr. Furuseth has six years of experience as management consultant at McKinsey & Co serving clients within the Pharma and Healthcare practice on commercial, operational and strategic topics.
Dr. Furuseth obtained his medical degree at Norwegian University of Science and Technology in 2004, and has three years of clinical practice.